Physician profile
Mark Anthony Ramiro
NPI 1467498774
$4,133.92
in general payments reported to CMS, 2019-2025
24 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $122 · 2021: $397 · 2022: $631 · 2023: $796 · 2024: $671 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $664.51 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $587.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $501.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $418.90 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $277.26 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $269.18 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $223.50 | 2019-2024 | |
| Pfizer INC. | $211.32 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.25 | 2021-2022 | |
| Lilly USA, LLC | $133.13 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $107.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.17 | 2020-2025 | Jardiance |
| Dexcom, INC. | $100.91 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $98.77 | 2021 | |
| Amgen INC. | $97.65 | 2023-2025 | Otezla, Repatha, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $67.31 | 2024-2025 | Veozah |
| Kyowa Kirin, INC. | $20.41 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $18.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.39 | 2022 | |
| Mylan Specialty L.P. | $16.42 | 2024 | Yupelri |
| Nevro Corp. | $16.22 | 2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.37 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.54 | 2024 | Voquezna |
| Genentech USA, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ramiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.